Browse treatments

…s in BC with high potential to overcome the challenges faced by cellular therapies in other solid tumors.Acknowledgements This work was supported …

…Background Chimeric Antigen Receptor (CAR) T cell therapy is an adoptive cell therapy in which cells are genetically modi…

…uire consolidative hematopoietic stem cell transplant following CAR T cell therapy to maintain durable responses. 1 We aim to improve long-term EF…

…product features required to achieve durable response following CAR T-cell therapy are unknown. Here, we performed a comprehensive analysis encomp…

…es with enhanced tumor progression and poor prognosis. However, chimeric antigen receptor (CAR) T cell therapy—an effective strategy in hematologic malignancies—has emerged a…

…ded by the folate receptor 1 gene (FOLR1) provides a target for chimeric antigen receptor (CAR) T-cell therapy. To date the dynamicity and the spatiotemporal dynamics of CAR …

…ently associated with bone metastases and poor prognosis. While chimeric antigen receptor (CAR) T cell therapy holds promise for mCRPC, clinical translation has been limited …

…) is a cancer-testis antigen broadly expressed in solid tumors. PRAME-targeting T cell therapy has already demonstrated deep and durable clinical responses in…

…elated deaths. There is currently only one clinical trial using CAR-T cell therapy to treat this disease and it targets ICAM-1, a protein with bro…

…Background CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed/refractory diffuse la…

…Background Adoptive immunotherapy using chimeric antigen receptor (CAR) T cells is a revolutionar…

…Background Cell-based therapies have untapped potential as treatments for a wide range of disea…